News & Updates

Circulating tumour DNA (ctDNA) testing after neoadjuvant chemotherapy (NAC) and radical cystectomy (RC) may inform patients with muscle-invasive bladder cancer (MIBC) of their risk for recurrence and allows personalized postoperative management in MIBC, results of the TOMBOLA trial have shown.

Excessive intrahepatic fat deposition (IPFD) appears to contribute to an increased risk of major pancreatic disease, suggests a recent study, noting the potential benefits of IPFD reduction in preventing pancreatitis and pancreatic cancer.

Prostate cancer patients treated with enzalutamide plus leuprolide have a higher probability of remaining free of distant metastasis, castration resistance, symptomatic progression, and first symptomatic skeletal event (SSE) at 5 years than those treated with leuprolide alone, as shown by the results of the EMBARK study.

Treatment with ipilimumab plus nivolumab improves long-term survival in melanoma patients with asymptomatic brain metastases, according to the results of the NIBIT-M2 trial presented at AACR 2026.